Aldeyra Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
16.50 |
5.20 |
74.92 |
93.43 |
130.01 |
205.73 |
| Przychód Δ r/r |
0.00% |
-68.48% |
1340.81% |
24.70% |
39.16% |
58.24% |
| Przychód (min) |
3.44 |
1.29 |
13.00 |
19.50 |
27.13 |
42.93 |
| Przychód (max) |
38.46 |
12.65 |
167.99 |
217.78 |
303.06 |
479.57 |
| EBITDA (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT (średnia) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| EBIT % |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
| Zysk netto (średni) |
-54.76 |
-47.83 |
6.53 |
0.50 |
39.85 |
65.43 |
| Zysk netto % |
-331.87% |
-919.73% |
8.72% |
0.54% |
30.66% |
31.81% |
| EPS (średnia) |
-0.93 |
-0.80 |
0.13 |
0.22 |
0.67 |
1.10 |
| Liczba analityków (Przychody) |
5 |
5 |
6 |
4 |
2 |
3 |
| Liczba analityków (EPS) |
6 |
4 |
5 |
4 |
3 |
2 |
| symbol |
ALDX |
ALDX |
ALDX |
ALDX |
ALDX |
ALDX |